Internet of Medical Things beats AI as top ranked growth driver among life science CEOs
A new report has revealed that 83% of life sciences CEOs view Internet of Medical Things (IoMT) devices as the…
All articles by Ross Law
Ross Law
Ross Henry Law is a reporter for Medical Device Network. His key interest areas in healthcare include regulation, mental health, neurology, oncology, and Alzheimer's disease. Ross also has extensive prior experience in covering the captive insurance, retail, and technology sectors.
-
-
The new safety mandate driving AI-ready pharmacovigilance
Regulatory expectations in the drug safety industry have evolved faster in the past five years than in the previous two…
-
When trillion‑member libraries meet physics: what diversity really means
Dr Karsten Eastman, CEO, Sethera Therapeutics, highlights the challenges around ‘true’ diversification in DNA libraries. In drug discovery, big numbers…
-
Podcast: JPM26’s dealmaking falls short of expectations
This year's J.P. Morgan Healthcare Conference wrapped up without the usual high level of M&A we've grown accustomed to. Boston…
-
JPM26: Anthropic advances healthcare presence with new AI toolkit
Anthropic has introduced Claude for Healthcare, a suite of artificial intelligence (AI)-based tools to assist healthcare providers, payers, and patients…
-
Magazine: Biopharma’s 2025 M&A boom
As we head into the new year, now is the time to look back on the activity seen in the…
-
The hidden crisis in regenerative medicine
Dr Tommy Rhee, CEO of RheeGen, outlines how FDA crackdowns have revealed dangerous and unethical tissue sourcing practices: Two decades…
-
Reeves’ Autumn Budget targets community health centres and NHS tech outlay
During the UK’s Autumn Budget, Rachel Reeves has unveiled further technology investments for the UK’s National Health Service (NHS) and,…
-
Magazine: Cleanroom chronicles
With tighter regulations around biopharma manufacturing and the emergence of advanced therapies, cleanroom design is being fundamentally reshaped. This month's…
-
Guardant and Zephyr AI pair up to advance cancer biomarker development
Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, as more precise tumour treatment…